AP NEWS

Systemic Idiopathic Juvenile Arthritis - Pipeline Review, H2 2018 - ResearchAndMarkets.com

September 17, 2018

DUBLIN--(BUSINESS WIRE)--Sep 17, 2018--The ” Systemic Idiopathic Juvenile Arthritis - Pipeline Review, H2 2018 ” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Systemic Idiopathic Juvenile Arthritis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Systemic Idiopathic Juvenile Arthritis and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 2 and 1 respectively.

Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Companies Featured

Alteogen Inc. Johnson & Johnson Livzon Pharmaceutical Group Inc. Mycenax Biotech Inc. Regeneron Pharmaceuticals Inc.

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/wgccxv/systemic?w=4.

View source version on businesswire.com:https://www.businesswire.com/news/home/20180917005472/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Musculoskeletal Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS PHARMACEUTICAL RESEARCH SCIENCE

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/17/2018 10:49 AM/DISC: 09/17/2018 10:49 AM

http://www.businesswire.com/news/home/20180917005472/en

AP RADIO
Update hourly